Management of Type 2 Diabetes in Frail Older Adults

Drugs & Aging, Journal Year: 2023, Volume and Issue: 40(9), P. 751 - 761

Published: July 11, 2023

Language: Английский

---

Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong

Diabetes Research and Clinical Practice, Journal Year: 2023, Volume and Issue: 197, P. 110576 - 110576

Published: Feb. 11, 2023

Language: Английский

---

Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(23), P. 7260 - 7260

Published: Nov. 23, 2023

Among the metabolic changes occurring during course of type 2 diabetes (T2DM) and diabetic kidney disease (DKD), impaired bone health with consequent increased fracture risk is one most complex multifactorial complications. In subjects disease, skeletal abnormalities may develop as a consequence both conditions. attempt to define holistic approach diabetes, potential effects various classes antidiabetic drugs on skeleton should be considered in setting normal function DKD. We reviewed main evidence these specific topics. Experimental studies reported beneficial harmful by different antidiabetics, few data available Clinical specifically designed evaluate antidiabetics have not been performed; notwithstanding, gleaned from randomized controlled trials intervention did completely confirm observations made basic research. aggregate, meta-analyses suggests positive metformin glucagon-like peptide-1 receptor agonists, neutral dipeptidyl peptidase-4 inhibitors, sodium–glucose cotransporter-2 sulfonylureas, negative insulin thiazolidinediones. As no clinical recommendations management currently include assessment among goal therapy, we propose an integrated aim defining patient-centered chronic (CKD) non-CKD patients. Future will help optimizing personalized more effective therapy diabetes.

Language: Английский

---

Association between sarcopenia and the foot-ankle function in type 2 diabetic foot ulcer

Diabetology & Metabolic Syndrome, Journal Year: 2024, Volume and Issue: 16(1)

Published: Nov. 13, 2024

The diabetic foot (DF) ulcer is the severe complication of type 2 diabetes mellitus (T2DM). Sarcopenia characterized as loss muscle mass and strength, resulting in increased risk fracture physical disability. may affect foot-ankle function DF patients, compromise quality life. aim was to clarify effect sarcopenia on patients with ulcer. In total 108 T2DM were enrolled. Based examination by dual energy X-ray absorptiometry (DXA) grip strength 5x sit-to-stand test, divided into non-sarcopenia groups. severity evaluated Wagner classification. American Orthopaedic Foot Ankle Society (AOFAS) Ankle-Hindfoot Score. showed advanced age, lower BMI, longer duration T2DM, more classification, reduced appendicular skeletal index (ASMI), transcutaneous oxygenpressure (TcPO2) prolonged time 5X test. stratified comparison analysis indicated that ulcer, TcPO2, aggravated impaired (P < 0.05). Multivariate Logistic factors deteriorating function. a key factor decreasing Thus, prevention could be considered part comprehensive therapy for

Language: Английский

---

Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways

International Journal of Experimental Pathology, Journal Year: 2024, Volume and Issue: 105(6), P. 219 - 234

Published: Oct. 13, 2024

Although single treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) or vitamin D

Language: Английский

---

Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(24), P. 17380 - 17380

Published: Dec. 12, 2023

Herein, we measured the antidiabetic and nephroprotective effects of sodium-glucose cotransporter-2 inhibitor (empagliflozin; SGLT2i) synthetic active vitamin D (paricalcitol; Pcal) mono- co-therapy against diabetic nephropathy (DN). Fifty mice were assigned into negative (NC) positive (PC) control, SGLT2i, Pcal, SGLT2i+Pcal groups. Following establishment DN, SGLT2i (5.1 mg/kg/day) and/or Pcal (0.5 µg/kg/day) used in designated groups (5 times/week/day). DN was affirmed PC group by hyperglycaemia, dyslipidaemia, polyuria, proteinuria, elevated urine protein/creatinine ratio, abnormal renal biochemical parameters. Renal SREBP-1 lipogenic molecule, adipokines (leptin/resistin), pro-oxidant (MDA/H2O2), pro-inflammatory (IL1β/IL6/TNF-α), tissue damage (iNOS/TGF-β1/NGAL/KIM-1), apoptosis (TUNEL/Caspase-3) markers also increased group. In contrast, lipolytic (PPARα/PPARγ), adiponectin, antioxidant (GSH/GPx1/SOD1/CAT), anti-inflammatory (IL10) molecules decreased Both monotherapies insulin levels mitigated profiles alongside lipid regulatory molecules, inflammation, oxidative stress. While monotherapy showed superior to their combination demonstrated enhanced remedial actions related metabolic control stress, apoptosis. conclusion, better than revealed nephroprotection, plausibly glycaemic with boosted antioxidative mechanisms.

Language: Английский

---

Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM

Journal of Biosciences and Medicines, Journal Year: 2024, Volume and Issue: 12(01), P. 115 - 125

Published: Jan. 1, 2024

In recent years, the progress of NAFLD has become an important health problem, and prevention or delay in is a major key point. Whether not to combine T2MD, people are interested mechanisms efficacy SGLT2i for NAFLD. this review, we summarized current clinical research on combination T2MD’s patients, latest evidence external animal experiments. These evidences will help us more accurately understand protective effects Lifestyle changes still essential prevent treat NAFLD, all kinds drugs that trials, may be one promising treatments.

Language: Английский

---

Estudio del efecto del tratamiento con fármacos antidiabéticos sobre el metabolismo óseo

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, Journal Year: 2024, Volume and Issue: 5(1), P. 90 - 95

Published: March 1, 2024

Resumen Objetivos La prevalencia de la diabetes mellitus tipo 2 (DMT2) está aumentando forma exponencial en todo el mundo, habiéndose comprobado que estos pacientes tienen mayor riesgo presentar fracturas óseas, con respecto a población sana, por lo resulta gran relevancia conocimiento del efecto los fármacos antidiabéticos sobre metabolismo óseo. Métodos Estudio estadístico descriptivo, retrospectivo, 106 tratamiento seis grupos antidiabéticos: insulina, inhibidores dipeptidilpeptidasa 4 (iDPP4), agonistas receptor péptido similar al glucagón 1 (arGLP1), sulfonilureas, cotransportador sodio-glucosa (iSGLT2) y pioglitazona, se determinaron osteocalcina (OC), fosfatasa alcalina ósea (FAO) telopéptido C-terminal colágeno o beta-crosslaps (β-CTx). Resultados Se encontraron concentraciones más elevadas β-CTx tratados pioglitazona iDPP4 (p=0,035), iSGLT2 (p=0,020) arGLP1 (p<0,001), siendo presentaron las bajas β-CTx. Conclusiones El antidiabético recibido padecen DMT2 puede afectar remodelado En nuestro estudio fueron mostraron resto fármacos, cual parece indicar conveniencia evitar mujeres postmenopáusicas DMT2. Los valores bajos β-CTx, podrían ejercer un beneficioso

---

Effects of antidiabetic drugs on bone metabolism

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, Journal Year: 2024, Volume and Issue: 5(1), P. 85 - 89

Published: March 1, 2024

Abstract Objectives The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding impact antidiabetic drugs on metabolism crucial. Methods A descriptive, retrospective study involving 106 receiving six groups drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two (SGLT2i); and pioglitazone, in which osteocalcin (OC), alkaline phosphatase (BAP) C-terminal telopeptide collagen or beta-crosslaps (β-CTx) were determined. Results β-CTx concentrations treated with as compared DPP4i (p=0.035), SGLT2i (p=0.020) GLP1ra (p<0.001). lowest observed GLP1ra. Conclusions Bone remodeling influenced by drug administered patients. In study, who received pioglitazone showed concentrations, other types drugs. This finding highlights convenience avoiding these drugs, especially postmenopausal women DMT2. associated suggests that agents could exert beneficial effects metabolism.

Language: Английский

---

Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”

American Journal of Cardiovascular Drugs, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Language: Английский

---